Pomerantz LLP Announces Class Action Lawsuit Against Hims & Hers Health, Inc.

Strategic Insights -

Pomerantz LLP has announced a class action lawsuit against Hims & Hers Health, Inc. (HIMS) regarding securities fraud and unlawful business practices. The lawsuit concerns allegations that Hims & Hers and its officers or directors have engaged in deceptive promotion and sales of counterfeit versions of the FDA-approved medication Wegovy. On June 23, 2025, Novo Nordisk, a pharmaceutical company, terminated its partnership with Hims & Hers due to the company's failure to adhere to laws regulating the sale of compounded drugs. As a result, Hims & Hers' stock price fell significantly, and investors who purchased shares during the class period may be eligible to seek damages.

Key Takeaways:

  • A class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS) alleging securities fraud and unlawful business practices.
  • The lawsuit concerns Hims & Hers' deceptive promotion and sales of counterfeit versions of the FDA-approved medication Wegovy.
  • Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, citing Hims & Hers' failure to adhere to laws regulating the sale of compounded drugs.
  • Hims & Hers' stock price fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025.
  • Investors who purchased shares of Hims & Hers during the class period may be eligible to seek damages.
  • Pomerantz LLP has a long history of recovering multimillion-dollar damages awards on behalf of class members.

Statistics:

  • Hims & Hers' stock price fell 34.63% to close at $41.98 per share on June 23, 2025.
  • The lawsuit concerns the sale of counterfeit versions of the FDA-approved medication Wegovy.